MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy
10. Mai 2018 08:30 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
14. Februar 2018 08:30 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
MyoKardia Announces Pricing of Proposed Public Offering of Common Stock
27. September 2016 18:47 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
MyoKardia Announces Proposed Public Offering of Common Stock
26. September 2016 16:48 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment...